JP2010524939A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524939A5
JP2010524939A5 JP2010504079A JP2010504079A JP2010524939A5 JP 2010524939 A5 JP2010524939 A5 JP 2010524939A5 JP 2010504079 A JP2010504079 A JP 2010504079A JP 2010504079 A JP2010504079 A JP 2010504079A JP 2010524939 A5 JP2010524939 A5 JP 2010524939A5
Authority
JP
Japan
Prior art keywords
carbons
nuclear receptor
alkyl
receptor binding
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524939A (ja
JP5815237B2 (ja
Filing date
Publication date
Priority claimed from US11/785,251 external-priority patent/US8158828B2/en
Application filed filed Critical
Publication of JP2010524939A publication Critical patent/JP2010524939A/ja
Publication of JP2010524939A5 publication Critical patent/JP2010524939A5/ja
Application granted granted Critical
Publication of JP5815237B2 publication Critical patent/JP5815237B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504079A 2007-04-16 2008-04-16 核内受容体結合剤 Expired - Fee Related JP5815237B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/785,251 2007-04-16
US11/785,251 US8158828B2 (en) 2005-11-28 2007-04-16 Nuclear receptor binding agents
PCT/US2008/004908 WO2008130571A1 (en) 2007-04-16 2008-04-16 Nuclear receptor binding agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014033091A Division JP5913400B2 (ja) 2007-04-16 2014-02-24 核内受容体結合剤

Publications (3)

Publication Number Publication Date
JP2010524939A JP2010524939A (ja) 2010-07-22
JP2010524939A5 true JP2010524939A5 (https=) 2011-06-02
JP5815237B2 JP5815237B2 (ja) 2015-11-17

Family

ID=39876311

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010504079A Expired - Fee Related JP5815237B2 (ja) 2007-04-16 2008-04-16 核内受容体結合剤
JP2014033091A Expired - Fee Related JP5913400B2 (ja) 2007-04-16 2014-02-24 核内受容体結合剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014033091A Expired - Fee Related JP5913400B2 (ja) 2007-04-16 2014-02-24 核内受容体結合剤

Country Status (4)

Country Link
US (1) US8158828B2 (https=)
JP (2) JP5815237B2 (https=)
KR (2) KR101563609B1 (https=)
WO (1) WO2008130571A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA201500845A1 (ru) * 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
EP3345607B1 (en) * 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
US20090130232A1 (en) * 2007-11-20 2009-05-21 Mohammed Zahra Composition and method for treatment of oral inflammation an ulceration
WO2009076548A1 (en) * 2007-12-13 2009-06-18 Cytori Therapeutics, Inc. Methods of inhibiting tumor development using adipose-derived regenerative cells
US8871751B2 (en) * 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
WO2010056979A1 (en) * 2008-11-14 2010-05-20 Immune Control, Inc. Phenothiazine derivatives for treatment of asthma
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US20140057946A1 (en) * 2012-08-23 2014-02-27 Gtx Estrogen receptor ligands and methods of use thereof
WO2013043304A1 (en) * 2009-02-23 2013-03-28 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
JP5611991B2 (ja) * 2009-02-23 2014-10-22 ジーティーエックス・インコーポレイテッド Ａｄｔのための医薬の製造におけるエストロゲン受容体リガンドの使用方法
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
ES2907862T3 (es) * 2009-12-10 2022-04-26 Univ Columbia Activadores de histona acetiltransferasa y usos de los mismos
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
EP2654428B1 (en) 2010-12-22 2018-02-14 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and usese thereof
US9809532B2 (en) 2011-06-10 2017-11-07 The Trustees Of Columbia University In The City Of New York Uses of histone acetyltransferase activators
EP2747562A4 (en) * 2011-08-23 2015-05-06 Gtx Inc ESTROGEN RECEPTOR LIGANDS AND METHOD FOR THEIR USE
EP2773721B1 (de) * 2011-11-01 2015-11-25 Merck Patent GmbH Organische elektrolumineszenzvorrichtung
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
LT2872482T (lt) 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9535071B2 (en) 2012-09-07 2017-01-03 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
US9433608B2 (en) 2013-05-08 2016-09-06 Howard University Compositions and method for treatment of ischemic neuronal reperfusion injury
CN107072969B (zh) * 2014-07-24 2020-04-21 艾森潘帕克制药股份有限公司 使用顺式氯米芬治疗雄激素剥夺疗法诱导的热潮红和骨丢失
US20220054429A1 (en) * 2015-10-27 2022-02-24 Jay Pharma, Inc. Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
WO2018208633A1 (en) * 2017-05-07 2018-11-15 China Medical University Methods and compositions for treating withdrawal syndrome
WO2022006470A1 (en) 2020-07-01 2022-01-06 Vanderbilt University Methods of treatment for a kidney disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE269213C (https=)
US3413339A (en) * 1964-06-18 1968-11-26 Parke Davis & Co Amine compounds and methods for their production
FR1536400A (fr) 1967-07-05 1968-08-16 Salicylanilides
US3960886A (en) * 1968-07-03 1976-06-01 Sterling Drug Inc. Substituted N-arylanilines
US3625972A (en) * 1968-07-03 1971-12-07 Sterling Drug Inc N-phenylbenzanilides
FR2140645A1 (en) 1971-06-11 1973-01-19 Grace W R Ltd Oxidation stabilised ester lubricants - contg mixed tert aromatic amines
US3838131A (en) * 1972-04-03 1974-09-24 Pfizer Di(dialkylamino alkoxy)phenanthridines as antiviral agents
US3838134A (en) * 1972-04-03 1974-09-24 G Gauthier Phenanthridinones as antiviral agents
US4373017A (en) * 1980-03-05 1983-02-08 Konishiroku Photo Industry Co., Ltd. Photosensitive compound and photosensitive material containing it
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
ATE148098T1 (de) 1991-02-21 1997-02-15 Sankyo Co Benzolderivate zum fördern der produktion des nervenwachstumsfaktors
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
EP0783303B1 (en) * 1994-09-16 2002-11-27 President And Fellows Of Harvard College Use of aromatic halides for treating mammalian cell proliferation
AU732881C (en) * 1994-09-16 2002-11-07 Children's Medical Center Corporation Triaryl and diaryl compounds, their analogues and uses thereof
GB9518994D0 (en) 1995-09-16 1995-11-15 Agrevo Uk Ltd Fungicides
WO1997030047A1 (en) 1996-02-17 1997-08-21 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
US20020156301A1 (en) * 1997-06-17 2002-10-24 Sumitomo Chemical Co., Ltd. Triphenylmethane derivatives and use thereof
JPH1171332A (ja) * 1997-06-17 1999-03-16 Sumitomo Chem Co Ltd トリフェニルメタン誘導体およびその用途
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6166013A (en) * 1998-07-30 2000-12-26 Abbott Laboratories Glucocortiocoid-selective agents
JP2002542187A (ja) * 1999-04-16 2002-12-10 アストラゼネカ・アクチエボラーグ エストロゲン−β受容体リガンド
JP4320089B2 (ja) 1999-07-06 2009-08-26 あすか製薬株式会社 フェニルスルファメート誘導体
DE19961372A1 (de) 1999-12-17 2001-06-21 Merck Patent Gmbh Verfahren zur Herstellung kombinatorischer Bibliotheken arylsubstituierter Amine
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
AU2001292320A1 (en) 2000-10-02 2002-04-15 Tanabe Seiyaku Co., Ltd. Benzylamine compound, process for producing the same, and intermediate therefor
US20020192310A1 (en) * 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
CN1896048A (zh) * 2001-03-16 2007-01-17 出光兴产株式会社 芳香氨基化合物的生产方法
JP2002322162A (ja) 2001-04-26 2002-11-08 Kyowa Hakko Kogyo Co Ltd チアゾリジン誘導体
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
CN1679956A (zh) * 2001-11-29 2005-10-12 Gtx公司 治疗因雄激素剥夺引起的症状
AU2003256616B2 (en) 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
WO2004026823A1 (en) 2002-09-20 2004-04-01 Pfizer Products Inc. Amide and sulfonamide ligands for the estrogen receptor
JP4176076B2 (ja) * 2002-11-08 2008-11-05 華為技術有限公司 無線ｌａｎユーザの在席情報のやりとりを行うための方法、システムおよび端末
JP2004307380A (ja) 2003-04-04 2004-11-04 Mitsubishi Chemicals Corp 新規化合物、電荷輸送材料、有機電界発光素子材料および有機電界発光素子
US7601739B2 (en) * 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
EA201500845A1 (ru) * 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
BRPI0713198A2 (pt) * 2006-07-19 2012-10-16 Osurf Ohio State University Res Foundation modulares seletivos de receptores de androgênio, seus análogos e derivados, e seus usos

Similar Documents

Publication Publication Date Title
JP2010524939A5 (https=)
RU2016103139A (ru) Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
JP2013513613A5 (https=)
JP2011502956A5 (https=)
RU2012105467A (ru) Триазолопиридиновое соединение и его действие в качестве ингибитора пролилгидроксилазы и индуктора выработки эритропоэтина
CA2407149A1 (en) Melanin-concentrating hormone antagonist
RU2012137501A (ru) Сигма-лиганды для применения при профилактике и/или лечении послеоперационной боли
JP2011527334A5 (https=)
JP2004524316A5 (https=)
JP2011137006A5 (https=)
JP2010536887A5 (https=)
JP2006516622A5 (https=)
RU2015142102A (ru) Соединение для лечения рака
JP2011521938A5 (https=)
JP2017508789A5 (https=)
JP2006501295A5 (https=)
JP2013508288A5 (https=)
TNSN07016A1 (en) Indole-2-carboxamidine derivatives as nmda receptor antagonists
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
NO20080877L (no) Fremgangsmater for behandling av substansrelaterte forstyrrelser
RU2014120477A (ru) Производные пиримидин-4-она и их применение в лечении, облегчении или профилактике вирусного заболевания
RU2011137324A (ru) Лиганды рецепторов эстрогенов и способы их применения
JP2010155827A5 (https=)
JP2017525740A5 (https=)
JP2018507191A5 (https=)